摘要
肿瘤细胞间和正常细胞间的钙离子信号的调节机制是不同的,这提供了对抗癌药的药理调整的新理解。但是,肝癌细胞和正常肝细胞对细胞外钙离子([Ca2+]e)的反应是否有异仍不清楚。今天的研究中,我们通过MTT和膜蛋白V/PI试验分别实测了暴露在额外钙离子([Ca2+]a)和阿霉素(ADM,一种治疗肝细胞癌的化疗剂)中的人正常胚胎肝L02细胞和人肝癌HepG2细胞的生长抑制,细胞凋亡和坏死几率。结果表明HepG2细胞中 [Ca2+]e引起的生长抑制,细胞凋亡和坏死几率以及细胞内钙离子浓度([Ca2+]i)下降比L02细胞高。此外,[Ca2+]e能选择性增强ADM引起的 HepG2 细胞的生长抑制,细胞凋亡和坏死,对L02细胞则不能。 ADM 和 [Ca2+]a联合治疗有在两种细胞路线中增加[Ca2+]i的重要相互作用效果,虽然两细胞中[Ca2+]i没有有意义的不同之处。为了进一步阐明关于 HepG2和L02细胞中[Ca2+]e选择性提升的机制,我们在 用ADM 或/和 [Ca2+]a治疗HepG2和L02细胞后研究了凋亡调控蛋白(bcl-2,bax和半胱天冬酶原3)和半胱天冬酶3的活动水平。结果显示与单用ADM治疗相比,用ADM和 [Ca2+]a治疗HepG2细胞提高了bax蛋白和半胱天冬酶3的活动水平,同时降低了bcl-2蛋白水平。但L02细胞没有有意义的变化。这些结果表明肝癌HepG2细胞比正常肝L02细胞对[Ca2+]e更敏感,且 [Ca2+]a能选择性增加ADM引起的 HepG2 细胞死亡。这种集中的凋亡前效果的机制可以归结于bax的上调和bcl-2的同时下调,接着是半胱天冬酶原3转换到执行细胞凋亡的半胱天冬酶3。现有数据显示钙离子是ADM的强化剂。
关键词: 阿霉素,细胞凋亡,bax,bcl-2,细胞外钙离子,HepG2细胞,L02细胞,半胱天冬酶原3
图形摘要
Current Cancer Drug Targets
Title:Extracellular Ca2+ Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Volume: 15 Issue: 6
Author(s): Xuexue Huang, Yuan Xu, Yanyi Liu, Hong Xie, Jiachun Wang and Zhigang Wu
Affiliation:
关键词: 阿霉素,细胞凋亡,bax,bcl-2,细胞外钙离子,HepG2细胞,L02细胞,半胱天冬酶原3
摘要: It has been shown that the regulatory mechanisms of Ca2+ signaling between tumor and normal cells are different, providing new insight into the pharmacological modulation of anticancer drugs. However, it remains unclear whether there is any difference between hepatoma and normal hepatic cells in their response to extracellular Ca2+ ([Ca2+]e). In the present study, the growth inhibition, apoptosis and necrosis rates of human normal embryo hepatic L02 and human hepatoma HepG2 cells exposed to additional calcium ([Ca2+]a)and adriamycin (ADM), a chemotherapeutic agent to treat hepatocellular carcinoma, were measured by MTT and annexin V/PI assays, respectively. The results showed that the growth inhibition, necrosis and apoptosis rates, as well as intracellular Ca2+ concentrations ([Ca2+]i) induced by [Ca2+]e in HepG2 cells were higher than those in L02 cells. Moreover, [Ca2+]e was able to selectively enhance ADM-induced growth inhibition, apoptosis and necrosis in HepG2 cells, but not in L02 cells. ADM and [Ca2+]a co-treatment had a significant interaction effect to increase [Ca2+]i in both cell lines, although there was no significant difference in [Ca2+]i between the two cells. To further elucidate the mechanisms involved in the selective promotion of [Ca2+]e in HepG2 and L02 cells, the levels of these apoptosis regulatory proteins (bcl-2, bax and procaspase-3) and the caspase-3 activity following treatment of HepG2 and L02 cells with ADM or/and [Ca2+]a were investigated. The results showed that treating HepG2 cells with [Ca2+]a and ADM increased the level of bax protein and caspase-3 activity while decreasing the level of bcl-2 protein, compared with treatment with ADM alone. However, no significant change was noted in L02 cells. These results indicate that hepatoma HepG2 cells are more sensitive to [Ca2+]e than normal hepatic L02 cells and that [Ca2+]a can selectively enhance ADMinduced cell death in HepG2 cells. The mechanism of this intensive pro-apoptotic effect can be ascribed to up-regulation of bax and the simultaneous down-regulation of bcl-2, followed by the switch from procaspase-3 to caspase-3, which executed apoptosis. The present data suggest the potency of the calcium ion as an enhancer of ADM.
Export Options
About this article
Cite this article as:
Xuexue Huang, Yuan Xu, Yanyi Liu, Hong Xie, Jiachun Wang and Zhigang Wu , Extracellular Ca2+ Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/156800961506150805151905
DOI https://dx.doi.org/10.2174/156800961506150805151905 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets The Targets of Curcumin
Current Drug Targets Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry The Stress Rheostat: An Interplay Between the Unfolded Protein Response (UPR) and Autophagy in Neurodegeneration
Current Molecular Medicine Biotransformation of Microcystins in Eukaryotic Cells - Possible Future Research Directions
Mini-Reviews in Medicinal Chemistry Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer
Mini-Reviews in Medicinal Chemistry Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Medicinal Chemistry Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Current Targets for Anticancer Drug Discovery
Current Drug Targets State-of-the-Art Magnetic Resonance Spectroscopy in Oncologic Imaging
Current Molecular Imaging (Discontinued) Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Flaxseed and Endotoxic Shock
Current Pharmaceutical Design